Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer.

CONCLUSIONS: Weekly docetaxel and platinum-based drug doublet combined with TR yielded promising results in stage III NSCLC, with high survival rates. The toxicity of this association is acceptable, with mainly manageable esophagitis. These findings warrant validation in a prospective study before considering this association for standard of care.
PMID: 32439358 [PubMed - as supplied by publisher]

Source: Cancer Radiotherapie - May 17, 2020 Category: Cancer & Oncology Authors: Kaderbhaï CG, Coudert B, Bertaut A, Adnet J, Favier L, Lagrange A, Peignaux-Casasnovas K, Mettey L, Tharin Z, Foucher P, Martin E Tags: Cancer Radiother Source Type: research